Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. (21st April 2017)

• Record Type: Journal Article
• Authors: Bilir, Cemil; Yıldız, İbrahim; Bilici, Ahmet; Ucar, Mahmut; Berk, Veli; Yıldız, Yaşar; Yazıcı, Ozan; İmamoğlu, Gökşen İnanç; Karadurmuş, Nuri; Pilancı, Kezban Nur; Arpacı, Erkan; Tanrıverdi, Özgür; Karcı, Ebru; Temiz, Süleyman; Nayır, Erdinc; Oktay, Esin; Dal, Pınar; Petekkaya, İbrahim; Varım, Ceyhun; Cinemre, Hakan
• Is Part Of: Cancer investigation. Volume 35:Number 4(2017)
• Page Start: 248
• Page End: 255
• Publication Date: 2017-04-21
• Subjects: Hemoglobin -- predictive -- renal cell carcinoma -- survival -- tyrosine kinase inhibitor; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2017.1292518
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: Background : There are insufficient predictive markers for renal cell carcinoma (RCC). Methods : A total of 308 metastatic RCC patients were analyzed retrospectively. Results : The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35 months ( p < .001) and 21.0 versus 11.36 months ( p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions : The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.